rituximab

all catalysts(0)

nothing on the calendar yet

News(10)

• Aura, Schrödinger trim workforces
  Follow along as BioSpace tracks job cuts and restructuring initiatives.
  biospace · 19h ago
• Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
  The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a regulatory setback and BeOne unveiled more positive Brukinsa data.
  biopharma_dive · 1mo ago
• An ADC specialist sinks on safety concerns for blood cancer drug
  Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”
  biopharma_dive · 2mo ago
• A Spanish biotech banks $87M to make differentiated ADCs
  Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.
  biopharma_dive · 2mo ago
• Dr McCann on the FDA Approval of Vepdegestrant for ESR1-Mutated, ER+ Advanced Breast Cancer
  Kelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.
  onclive · 3mo ago
• Honesty and Humor Provide Hope in Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Annie Bond
  Dr Nunnery and Annie Bond discuss breast cancer survivorship and patient advocacy.
  onclive · 3mo ago
• Dr Postow on an Ideal Post-ICI Monitoring Framework in Melanoma
  Michael A. Postow, MD, discusses the importance of long-term multidisciplinary follow-up for patients with melanoma treated with ICIs.
  onclive · 3mo ago
• Dr Postow on the Timing of Delayed or Re-Emergent irAEs in Melanoma
  Michael A. Postow, MD, discusses the evolving understanding of ICIs in melanoma and the unique toxicity profiles associated with these agents.
  onclive · 3mo ago
• Temple Health’s Fox Chase Cancer Center and Labcorp Collaborate to Test Ultra-Sensitive Blood-Based Assay for Early-Stage Lung Cancer Recurrence Risk
  A Fox Chase Cancer Center study will evaluate a tumor-informed, whole-genome sequencing–based test to assess recurrence risk in early-stage NSCLC.
  onclive · 3mo ago
• GU Cancer Experts Highlight Top Abstracts to Watch During ASCO 2026
  We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.
  onclive · 3mo ago